Literature DB >> 34357490

Circ_CLIP2 promotes glioma progression through targeting the miR-195-5p/HMGB3 axis.

Bing Xiao1, Shi-Gang Lv1, Miao-Jing Wu1, Xiao-Li Shen1, Wei Tu1, Min-Hua Ye2, Xin-Gen Zhu3.   

Abstract

BACKGROUND: Circular RNA (circRNA) has been demonstrated to play key roles in regulating glioma progression. Understanding the regulatory mechanism of circRNA in glioma is vital to reveal the pathogenesis of glioma and develop novel therapeutic strategies. Therefore, our study focuses on the role and underlying mechanism of Circ_CLIP2 in glioma.
METHODS: The expression of Circ_CLIP2, miR-195-5p and HMGB3 in glioma cells and tissues were analyzed using qRT-PCR. Cell proliferation was determined with colony formation and MTT assays. Cell cycle and apoptosis were examined by flow cytometry. Western blot was conducted for analyzing HMGB3, PCNA, Bax, Bcl-2, cleaved-caspase 3, Wnt-1 and β-catenin. Dual-luciferase reporter assay was measured to investigate the interaction among Circ_CLIP2, miR-195-5p and HMGB3.
RESULTS: The expression of Circ_CLIP2 and HMGB3 were increased while miR-195-5p was down-regulated in glioma cells and patients. Silencing of Circ_CLIP2 inhibited cell proliferation, enhanced cell apoptosis and inhibited the Wnt/β-catenin signaling pathway. Circ_CLIP2 suppressed miR-195-5p expression by directly sponging miR-195-5p. MiR-195-5p inhibited HMGB3 expression via directly targeting HMGB3. Knockdown of miR-195-5p facilitated cell proliferation, inhibited cell apoptosis and activated Wnt/β-catenin signaling, which were reversed by silencing of HMGB3.
CONCLUSION: Knockdown of Circ_CLIP2 suppresses glioma progression by targeting miR-195-5p/HMGB3 thus inhibiting Wnt/β-catenin signaling. This study may provide potential therapeutic targets against glioma.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Apoptosis; Circ_CLIP2; Glioma; HMGB3; Proliferation; Wnt/β-catenin signaling pathway; miR-195-5p

Mesh:

Substances:

Year:  2021        PMID: 34357490     DOI: 10.1007/s11060-021-03814-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  38 in total

Review 1.  Central nervous system gliomas.

Authors:  Michele Reni; Elena Mazza; Silvia Zanon; Gemma Gatta; Charles J Vecht
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-22       Impact factor: 6.312

Review 2.  The epidemiology of glioma in adults: a "state of the science" review.

Authors:  Quinn T Ostrom; Luc Bauchet; Faith G Davis; Isabelle Deltour; James L Fisher; Chelsea Eastman Langer; Melike Pekmezci; Judith A Schwartzbaum; Michelle C Turner; Kyle M Walsh; Margaret R Wrensch; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

Review 3.  Apoptosis in gliomas: molecular mechanisms and therapeutic implications.

Authors:  Joachim P Steinbach; Michael Weller
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

Review 4.  Glioma Subclassifications and Their Clinical Significance.

Authors:  Ricky Chen; Matthew Smith-Cohn; Adam L Cohen; Howard Colman
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

5.  Treatment of Gliomas: How did we get here?

Authors:  Michelle M Chowdhary; Chibawanye I Ene; Daniel L Silbergeld
Journal:  Surg Neurol Int       Date:  2015-02-13

6.  Evaluation of cumulative prognostic score based on pretreatment plasma fibrinogen and serum albumin levels in patients with newly diagnosed high-grade gliomas.

Authors:  Zhen-Qiang He; Hao Duan; Chao Ke; Xiang-Heng Zhang; Cheng-Cheng Guo; Fuad Al-Nahari; Ji Zhang; Zheng-He Chen; Yin-Sheng Chen; Zhi-Gang Liu; Jian Wang; Zhong-Ping Chen; Xiao-Bing Jiang; Yong-Gao Mou
Journal:  Oncotarget       Date:  2017-07-25

Review 7.  Non-Coding RNAs in Glioma.

Authors:  Ryte Rynkeviciene; Julija Simiene; Egle Strainiene; Vaidotas Stankevicius; Jurgita Usinskiene; Edita Miseikyte Kaubriene; Ingrida Meskinyte; Jonas Cicenas; Kestutis Suziedelis
Journal:  Cancers (Basel)       Date:  2018-12-22       Impact factor: 6.639

8.  MicroRNAs in Human Malignant Gliomas.

Authors:  Masahiro Mizoguchi; Yanlei Guan; Koji Yoshimoto; Nobuhiro Hata; Toshiyuki Amano; Akira Nakamizo; Tomio Sasaki
Journal:  J Oncol       Date:  2012-07-10       Impact factor: 4.375

Review 9.  Functions and clinical significance of circular RNAs in glioma.

Authors:  Jikui Sun; Banban Li; Chang Shu; Quanfeng Ma; Jinhuan Wang
Journal:  Mol Cancer       Date:  2020-02-15       Impact factor: 27.401

10.  PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo.

Authors:  Fangfang Li; Zongliang Liu; Heyuan Sun; Chunmei Li; Wenyan Wang; Liang Ye; Chunhong Yan; Jingwei Tian; Hongbo Wang
Journal:  Acta Pharm Sin B       Date:  2019-09-18       Impact factor: 11.413

View more
  1 in total

1.  Glaucocalyxin A Inhibits the Malignant Progression of Epithelial Ovarian Cancer by Affecting the MicroRNA-374b-5p/HMGB3/Wnt-β-Catenin Pathway Axis.

Authors:  Feng Chen; Fang Sun; Xia Liu; Jing Shao; Bei Zhang
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.